

	Month (%)	Quarter (%)	FYTD (%)	1 Year (%)	2 Years (% p.a.)	3 Years (% p.a.)	Since Inception <sup>^</sup> (% p.a.)	Since Inception Cumulative <sup>^</sup> (%)
Perennial Better Future Trust (Net)	+9.9	-6.7	+9.9	-9.9	+11.0	+7.6	+9.1	+48.0
S&P/ASX Small Ordinaries Accumulation Index	+11.4	-9.9	+11.4	-10.9	+8.6	+2.5	+4.3	+20.9
<b>Value Added</b>	<b>-1.5</b>	<b>+3.2</b>	<b>-1.5</b>	<b>+1.0</b>	<b>+2.4</b>	<b>+5.1</b>	<b>+4.8</b>	<b>+27.1</b>

<sup>^</sup>Since inception: 1 February 2018. Past performance is not a reliable indicator of future performance.

### Overview

The benchmark rebounded in July as concerns around higher inflation and interest rates abated. The Trust finished the month up 9.9%, underperforming the benchmark by 1.5%.

It is over four years since the inception of the Trust. It is a key goal of the Trust to demonstrate that there is no performance trade-off to invest for shaping a better future. Since inception, the Trust has delivered a +9.1% p.a. return net of fees, outperforming the benchmark by +4.8% p.a.

Positive contributors to relative performance this month included Telix Pharmaceuticals (+63.1%), Next Science (+50.0%) and Healthco Healthcare & Wellness REIT (25.5%).

Negative contributors this month included KMD Brands (-0.5%) Integral Diagnostics (+2.0%) and Nitro Software (-14.2%).

### Better Future Highlight

Portfolio holding Telix Pharmaceuticals announced two developments during the month. The company commenced global sales of the company's Illucix product for the imaging of prostate cancer during the June quarter. Pleasingly global sales exceeded market expectations with more than \$22m in sales during the quarter. Sales are expected to increase further in subsequent quarters as US reimbursement status was only granted after the end of the quarter. The initial sales outcomes suggests there is significant demand for the product and urologists are seeing benefits for patients from Telix's technology.

The company also announced the completion of patient recruitment for the company's Phase III renal (kidney) cancer imaging study. The company's product has previously received "Breakthrough Designation" from the U.S. Food and Drug Administration (FDA). The product seeks to distinguish between benign and malignant renal lesions. Current imaging cannot reliably make this distinction, leading to invasive biopsy procedures which are not always necessary as up to 80% are malignant. Telix expects to report the outcome from the study later in 2022.

### Perennial Better Future Trust

The aim of the Trust is to grow the value of your investment over the long term by investing in companies predominantly outside the S&P/ASX Top 50 Index that conduct business taking into account environmental, social and governance ("ESG") considerations and/or businesses that are making a positive contribution to creating a better future. The Trust seeks to provide a total return (after fees) that exceeds the S&P/ASX Small Ordinaries Accumulation Index measured on a rolling three-year basis.

#### Portfolio Manager

Damian Cottier

#### APIR Code

WPC5600AU

#### Distribution Frequency

Annually (if any)

#### Minimum Initial Investment

\$25,000

#### Trust Inception Date

1 February 2018

#### Fees


1.20% p.a. + Performance fee



Value of A\$100,000 since inception (1 February 2018) of the Better Future Trust as at 31 July 2022.

Performance shown net of fees with distributions reinvested. Does not take into account any taxes payable by an investor. Past performance is not a reliable indication of future performance.

### Portfolios Contribution to the UN Sustainable Development Goals



**Total Contribution: 67.33%**  
(equal to 54.83% social impact contribution and 12.5% environmental impact contribution)

## Trust Review

The benchmark rebounded in July as concerns around higher inflation and interest rates abated. The Trust finished the month up 9.9%, underperforming the benchmark by 1.5%.

It is over four years since the inception of the Trust. It is a key goal of the Trust to demonstrate that there is no performance trade-off to invest for shaping a better future. Since inception, the Trust has delivered a +9.1% p.a. return net of fees, outperforming the benchmark by +4.8% p.a.

Positive contributors to relative performance this month included Telix Pharmaceuticals (+63.1%), Next Science (+50.0%) and Healthco Healthcare & Wellness REIT (+25.5%).

Negative contributors this month included KMD Brands (-0.5%) Integral Diagnostics (+2.0%) and Nitro Software (-14.2%).

As discussed overleaf, Telix Pharmaceuticals announced better than expected sales revenue after the commercial launch of the company's Illucix prostate cancer imaging product.

Next Science announced improved sales results and that now over 258 surgeons in 142 US hospitals are using the company's Xperience products which prevent surgical site infection, primarily in orthopaedic surgery. There were no material announcements from Healthco with performance reversing some of the stock's recent underperformance.

KMD Brands released a trading update where guided FY22 profit was weaker than expected due to COVID disruptions in Australian and New Zealand in the early part of the calendar year, with conditions having improved as the year progressed.

Integral Diagnostics also announced a weaker than expected profit result as COVID and absenteeism impacted both demand for diagnostic imaging and costs. We expect conditions for Integral Diagnostics will improve over the coming year as these headwinds abate. Nitro Software announced weaker than expected sales guidance for the 2022 calendar year as it is restructuring the business to place greater focus on profitability rather than sales growth.

Genetic Signatures released a solid quarterly update and announced that it has completed recruitment for a US clinical trial for the company's innovative enteric kit to detect gastrointestinal illness. This is a key step to support an application to the US Food and Drug Administration which is required before it can commence sales in the substantial US market. The company has some success with the enteric kit offshore having won a tender to supply enteric kits to Public Health Wales which it is in the process of implementing. The enteric kit greatly reduces the turnaround time for test results and largely automates a very manual process. This is likely to significantly improve outcomes for patients, pathology companies and medical professionals.

At month end, the portfolio held 47 stocks and cash of 8.4%.

At July end, the weighted average Perennial-derived Environmental, Social, Governance and Engagement ("ESGE") Score of the Trust was 7.3 which is 27% higher than the benchmark ESGE Score of 5.7.



**Invest Online Now**

## Contact us



Level 27, 88 Phillip Street  
Sydney NSW 2000



1300 730 032



invest@perennial.net.au



www.perennial.net.au

### Signatory of:



Issued by: Perennial Partners Limited (ABN 90 612 829 160) (Perennial) as a Corporate Authorised Representative (No. 1293138) of the Investment Manager Perennial Value Management Limited (ABN 22 090 879 904/AFSL No. 247293). Responsible Entity: Perennial Investment Management Limited (ABN 13 108 747 637/AFSL No. 275101). This promotional statement is provided for information purposes only. Accordingly, reliance should not be placed on this promotional statement as the basis for making an investment, financial or other decision. This promotional statement does not take into account your investment objectives, particular needs or financial situation and is not intended to constitute advertising or advice of any kind and you should not construe the contents of promotional statement as legal, tax, investment or other advice. This promotional statement does not constitute an offer or inducement to engage in an investment activity nor does it form part of any offer documentation, offer or invitation to purchase, sell or subscribe for interests in any type of investment product or service. You should read and consider any relevant offer documentation applicable to any investment product or service and consider obtaining professional investment advice tailored to your specific circumstances before making any investment decision. While every effort has been made to ensure the information in this promotional statement is accurate, its accuracy, reliability or completeness is not guaranteed. Past performance is not a reliable indicator of future performance. Gross performance does not include any applicable management fees or expenses. Net performance is based on redemption price for the period and assumes that all distributions are reinvested. Fees indicated reflect the maximum applicable. Contractual arrangements, including any applicable management fee, may be negotiated with certain large investors. Investments in the Trusts must be accompanied by an application form. The current relevant product disclosure statements, additional information booklet, application forms and target market determination can be found on Perennial's website [www.perennial.net.au](http://www.perennial.net.au). Use of the information on our website is governed by Australian law and is subject to the terms of use. No distribution of this material will be made in any jurisdiction where such distribution is not authorised or is unlawful. The rating issued 09/2021 is published by Lonsac Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsac). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsac assumes no obligation to update. Lonsac uses objective criteria and receives a fee from the Fund Manager. Visit [lonsac.com.au](http://lonsac.com.au) for ratings information and to access the full report. © 2022 Lonsac. All rights reserved. The Zenith Investment Partners (ABN 27 103 132 672/AFSL 226870) (Zenith) rating (assigned WPCS6004U February 2022) referred to in this piece is limited to "General Advice" (s706B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at [Fund Research Regulatory Guidelines](http://Fund Research Regulatory Guidelines). The rating is issued by SuperRatings Pty Ltd ABN 95 100 192 285/AFSL 311880 (SuperRatings). Ratings are general advice only and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and SuperRatings assumes no obligation to update. SuperRatings uses objective criteria and receives a fee for publishing awards. Visit [superratings.com.au](http://superratings.com.au) for ratings information and to access the full report. © 2022 SuperRatings. All rights reserved.

## ESG Activity

Our ESG activity during the month included:

- This month, Eroad and G8 Education began reporting their emissions profile following engagements with the company on measuring, disclosing and aligning GHG emissions with the Paris Agreement.
- We engaged on gender diversity, GHG emissions, Say on Pay Vote and remuneration disclosure with Pacific Edge.
- We wrote to Chorus informing them that have assumed lead investor role for the company on the 40:40 Vision. We will meet with the company to discuss joining the Vision and gender balance in executive teams later in September.
- APM Group launched the first Social Loan Linked corporate debt facility in Australia.
- The Perennial Reconciliation Action Plan Working Group attended the Dyarubbin exhibition at the State Library as part of NAIDOC Week.

### Top 5 Active Positions

	Trust (%)	Index (%)
Meridian Energy	4.4	0.0
Bendigo and Adelaide Bank	3.6	0.0
Spark New Zealand	3.6	0.4
Integral Diagnostics	3.5	0.3
Telix Pharmaceuticals	3.4	0.7

## Better Future and ESG Team

Damian Cottier  
Portfolio Manager

Emilie O'Neill  
Co-Head of ESG &  
Equities Analyst



CERTIFIED BY RIAA



The Perennial Better Future Trust has been certified by the Responsible Investment Association Australasia according to the strict operational and disclosure practices required under the Responsible Investment Certification Program. See [www.responsibleinvestments.com.au](http://www.responsibleinvestments.com.au) for details<sup>1</sup>.

1. The Responsible Investment Certification Program does not constitute financial product advice. Neither the Certification Symbol nor RIAA recommends to any person that any financial product is a suitable investment or that returns are guaranteed. Appropriate professional advice should be sought prior to making an investment decision. RIAA does not hold an Australian Financial Services Licence.